Articles

PP22 Maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease

BJH - 2018, issue Abstract Book BHS, february 2018

J. Muller MSc, A. Bolomsky , S. Dubois , E. Duray , Y. Beguin MD, PhD, H. Ludwig , R. Heusschen PhD, J. Caers MD, PhD

Read more

Multiple myeloma bone disease: from mechanisms to next generation therapy

BJH - volume 8, issue 2, march 2017

R. Heusschen PhD, J. Muller MSc, N. Withofs MD, PhD, prof. F. Baron , Y. Beguin MD, PhD, J. Caers MD, PhD

SUMMARY

Multiple myeloma bone disease is a major cause of morbidity and mortality in multiple myeloma patients and persists even in patients in remission. Multiple myeloma bone disease is caused by an uncoupling of bone remodelling, with increased osteoclast activity and decreased osteoblast activity, culminating in lytic bone destruction. Bisphosphonates are the current standard-of-care but new therapies are needed. As the molecular mechanisms controlling multiple myeloma bone disease are increasingly understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds show promising results. In this review, we provide a comprehensive overview of the biology of multiple myeloma bone disease, summarise its current clinical management and discuss preclinical and clinical data on next generation therapies.

(BELG J HEMATOL 2017;8(2):66–74)

Read more

O.3 Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma and its associated Bone Disease

BJH - volume 8, issue Abstract Book BHS, february 2017

R. Heusschen PhD, A. Bolomsky , K. Schlangen , K. Schönfelder , J. Muller MSc, W. Schreiner , N. Zojer , J. Caers MD, PhD, H. Ludwig

Read more

PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Ehx , G. Fransolet , L. Delens , J. Muller MSc, Y. Beguin MD, PhD, S. Humblet-Baron , M. Hannon , prof. F. Baron

Read more

PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Hannon , C. Grégoire MD, J. Muller MSc, G. Fransolet , L. Delens , Y. Beguin MD, PhD, G. Ehx , prof. F. Baron

Read more

P12 The glycan-binding galectin-1 is involved in osteoclast biology

BJH - volume 8, issue Abstract Book BHS, february 2017

J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD

Read more

O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

BJH - volume 7, issue Abstract Book BHS, january 2016

R. Heusschen PhD, J. Muller MSc, M. Binsfeld , E. Plougonven , N. Mahli , G. Carmeliet , A. Léonard , prof. F. Baron , M. Cohen-Solal , K. Vanderkerken PhD, Y. Beguin MD, PhD, E. Menu , J. Caers MD, PhD

Read more